NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: FDC · data 2026-10-30
FDC Ltd.
In plain words
Price: 20.4% below its 52-week high of ₹473.6.
Delivery: 48.0% of traded shares were kept for delivery over the last 10 sessions, against 53.4% over the last 60.
Latest results: a net profit of ₹79 cr for the quarter ended Dec 2023.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,289 cr |
| Net profit (last 12 months) | ₹313 cr |
| Sales growth, 3 years (yearly) | 6.8% |
| Profit growth, 3 years (yearly) | 13.2% |
Latest results in brief (Q3 FY26)
FDC Q3 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹464.71 crore, up 0.1% YoY.
Net profit was ₹28.3 crore, down 24.5% YoY.
Operating margin was 11.2% (10.1% a year ago).
EPS was ₹1.74, down 23.7% YoY.
FDC के Q3 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹464.71 करोड़; पिछले साल की तुलना में 0.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹28.3 करोड़; पिछले साल की तुलना में 24.5% की गिरावट।
ऑपरेटिंग मार्जिन: 11.2% (एक साल पहले 10.1%)।
EPS: ₹1.74; पिछले साल की तुलना में 23.7% की गिरावट।
FDCના Q3 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹464.71 કરોડ; ગયા વર્ષની સરખામણીએ 0.1% વધારો.
ચોખ્ખો નફો: ₹28.3 કરોડ; ગયા વર્ષની સરખામણીએ 24.5% ઘટાડો.
ઓપરેટિંગ માર્જિન: 11.2% (એક વર્ષ પહેલાં 10.1%).
EPS: ₹1.74; ગયા વર્ષની સરખામણીએ 23.7% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 40.8% over the last 20 sessions vs 46.6% in the 40 before (0.88x); shares delivered per day 0.99x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 45/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider ● Dividend
- 27 Oct 26Results Q2 FY27 results: profit +76.3% YoY +8.7% next session
- 21 Sept 26Insider SAST disclosure: Mohan Anand Chandavarkar Trust +1 acquired 50,30,086 shares +1.1% next session
- 5 Aug 26Results Q1 FY27 results: profit +9.2% YoY -8.1% next session
- 17 Jul 26Results Q4 FY26 results: profit +167.4% YoY -0.9% next session
- 11 Feb 26Dividend Dividend ₹5 (ex-date) -2.2% next session
- 5 Feb 26Results Q3 FY26 results: profit −24.5% YoY -4.7% next session
- 5 Nov 25Results Q2 FY26 results: profit −61.3% YoY -5.7% next session
- 7 Aug 25Results Q1 FY26 results: profit +1.5% YoY 0.0% next session
- 28 May 25Results Q4 FY25 results: profit −16.4% YoY -3.6% next session
- 13 Feb 25Results Q3 FY25 results: profit −52.7% YoY -8.1% next session
- 22 Nov 24Dividend Dividend ₹5 (ex-date) +1.8% next session
- 7 Nov 24Results Q2 FY25 results: profit +5.1% YoY -6.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2023 | ₹458 cr | ₹79 cr | — | 18.3% | 4.86 |
| Sept 2023 | ₹486 cr | ₹70 cr | — | 15.7% | 4.22 |
| Mar 2023 | ₹435 cr | ₹31 cr | — | 11.3% | 1.85 |
Shareholding trend
| Holder | Sept 2026 | Sept 2025 |
|---|---|---|
| Promoters | 69.66% | 69.66% |
| Foreign institutions (FII) | 1.58% | 2.43% |
| Domestic institutions (DII) | 6.59% | 6.82% |
| Mutual funds | 6.48% | 6.63% |
| Retail investors | 13.07% | 12.25% |
| Number of shareholders | 54,621 | 54,157 |
Common questions
What was FDC Ltd.'s latest quarterly profit?
FDC Ltd. reported a net profit of ₹79 cr for the quarter ended Dec 2023, on revenue of ₹458 cr.
How much do promoters hold in FDC Ltd.?
Promoters held 69.66% of FDC Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is FDC Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is FDC Ltd.'s P/E ratio?
About 19.6, based on the last 12 months' earnings and a price of ₹377 (data 2026-10-30).
What is the 52-week high and low of FDC Ltd.?
The 52-week high is ₹473.6 and the 52-week low is ₹312.95.
Similar companies
Supriya Lifescience Limited (SUPRIYA) · Morepen Laboratories Limited (MOREPENLAB) · Innova Captab Limited (INNOVACAP) · Sun Pharma Advanced Research Co. Ltd. (SPARC) · Senores Pharmaceuticals Ltd. (SENORES)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FDC in NSE Scanner →